Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Model system identifies new FHV-1 drug
Black cat eye
The team identified the drug while developing a model to test drugs that treat feline eye infections.

Raltegravir requires only once-a-day dosing

A model system developed to test medication for feline herpesvirus 1 (FHV-1) has identified a new drug that only needs to be applied once-a-day.

Identified by scientists at Cornell's College of Veterinary Medicine, raltegravir is used in humans to treat HIV infections, but it had never been used to treat FHV-1 in cats.

“We found that it is very effective against FHV-1. It even worked when we applied the drug only once every 24 hours,” says study leader Dr Gerlinde Van de Walle.

The team identified the drug while developing a model to test drugs that treat feline eye infections.

Described in the Journal of General Virology, the new model used corneas donated from cats that died of causes other than eye disease. Researchers say this method offers a better reflection of what happens in the eyes of a cat, than models consisting of cells in a petri dish.

In the study, the team applied the FHV-1 virus to some of the corneas and tested the effectiveness of two commonly prescribed drugs: cidofovir and acyclovir.

Both drugs cleared the infection when applied every 12 hours, but cidofovir was more effective.

The team then used the model system to test raltegravir. They found that it was just as effective as other drugs for treating FHV-1 infections and only needed to be administered once a day.

Dr Walle says that she eventually hopes to see the drug tested in a well-controlled clinical trial.

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'